Targeted Strategies for Today's Evolving Markets

FluoroPharma Medical, Inc. (FPMI)

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing four different imaging agents to fulfill multiple critical unmet medical needs while providing clinicians important tools for detecting and assessing pathology before critical manifestations of disease.

According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future. With one in three patients dying because of heart disease, FluoroPharma's cardiovascular program addresses the largest segment of the nuclear medicine market. In fact, every three seconds a U.S. patient is injected with a drug FluoroPharma’s products target, providing considerable opportunity for rapid growth and profitability.

Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease non-invasively before anatomical manifestation is identified by offering visualization of biological processes at the molecular and cellular level. Featuring higher resolution scans with only a third of the radiation dose, as well as higher levels of reimbursement, PET has become the preferred imaging technology for a variety of diseases and disorders.

FluoroPharma's comprehensive technology platform promises to help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment and better patient outcomes. To date, the company has been issued patents related to its portfolio of imaging compounds in the United States, Europe, China, Japan, Canada, Australia, Finland, Portugal, Ireland, and Mexico. With a solid and experienced management team in place and the necessary resources to advance clinical development, FluoroPharma is well positioned to capitalize on its superior imaging technology.

Key Investment Highlights

  • Clinical Trials Confirmed Technologies are Safe and are Now Establishing their Efficacy
  • Intellectual Property in Place to Protect Proprietary Innovations Around the World
  • Cash On Hand to Advance Business Strategy
  • Technology Targets Multiple, Multimillion Dollar Healthcare Markets with Strong / Unmet Medical Needs
 
FluoroPharma Medical, Inc. (FPMI)
 
Board of Directors

Thijs Spoor
Chairman of the Board, CEO & President

Walter Witoshkin
Director

Peter Conti, MD, PhD
Director, Scientific Advisory Board

Lawrence Atinsky
Director

Joseph A. Pierro
Director

Management Team

Thijs Spoor
Chairman of the Board, CEO & President

Boyan Goumnerov, MD
COO & Vice President Clinical Trials

Tamara Rhein
CFO

 

 

 

Blog

Management Team

Intellectual Property

Presentation

Website